ArticleJournal of cosmetic dermatology2026
The ARTIST Post-Market Study: Evaluating a High G' Hyaluronic Acid (HA) Injectable for Chin Combined With Midface HA Filler Treatments.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aesthetic Chin Retrusion Enhancement With Non-animal Stabilized Hyaluronic Acid-High Density (NASHA-HD™) Filler.Cureus · 2026Article
- The ARTIST Post-Market Study: Evaluating a High G' Hyaluronic Acid (HA) Injectable for Chin Combined With Midface HA Filler Treatments.Journal of cosmetic dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundA novel hyaluronic acid (HA) injectable (Restylane Shaype, HA
aimsThis prospective, 8-week, multicenter, post-market study evaluated three treatment algorithms, i.e., the Shayping Technique, for subjects with multiple aesthetic needs, including HA PATIENTS/
methodsSubjects ≥ 18 years were assigned to one of the following treatments: Group 1: HA
resultsThe GAIS responder rate ("improved," "much improved," or "very much improved") was 100% in all groups at Week 8 (primary endpoint) and Week 4 as assessed by the investigator and by subject self-assessment at Weeks 4 and 8. Overall subject and investigator satisfaction with treatment was high, and the safety profile for all product combinations was favorable, with no unexpected AEs.
conclusionsTreatment with HA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.